Company intelligence / Profile preview

Tocqueville

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Tocqueville Therapeutics is a biotechnology company focused on developing next-generation immunotherapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform to expand antigen-specific regulatory T cells (Tregs) in vivo, aiming to restore immune tolerance without systemic immunosuppression. Founded by pioneers in the field of Treg biology, Tocqueville is advancing a pipeline of therapies designed to treat conditions such as Type 1 diabetes and lupus. Their approach combines deep expertise in T-cell receptor (TCR) engineering and cytokine biology to create highly targeted treatments.

Therapeutic areas: EndocrinologyImmunology
Modalities: Cell therapyT cell receptor engineered T cell therapyMonoclonal antibody
Industry: Biotech

Partnerships

Sorbonne UniversityINSERM

Beyond the preview

Go deeper on Tocqueville.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tocqueville.

Explore the full profile